On behalf of the Scientific Program Planning Committee and PDA, we are proud to invite you to the Visual Inspection Forum to take place in Berlin, Germany, 26-27 April!
We are excited to return to an on-site meeting!
This forum will provide a platform to present and discuss new developments in the field of visual inspection (VI). This year we will have a special focus on the use of automated visual inspection (AVI) technology to meet increasing demands for injectable products. Discussion will include both inspection hardware and software along with validation strategies necessary to deploy this technology. The emergence of Artificial Intelligence (AI) and Deep Learning (DL) as applied to AVI will be also part of these discussions.
Manual inspection is the reference method fond in all global pharmacopeias and continues to be widely used. Practical discussions on inspector training and routine manual inspection are planned. A holistic view of the VI process including control strategies, AQL inspection, defect trending and continuous process improvement will be included.
Special consideration is given to difficult to inspect parenteral (DIP) products such as lyophilized and biopharmaceutical products, and those in special packing types.
The regulatory and compendial requirements that govern the inspection process will also be discussed. On 20 December 2017, the long-awaited revision to Annex 1 of the EU GMP Guidelines was published. While the currently valid Annex 1 only briefly touches on the important topics of container closure integrity (CCI) control and VI, this revision contains significantly expanded requirements. The new requirements encourage further discussion of the correct understanding and implementation of VI within the pharmaceutical manufacturing supply chain and provide only one of this year’s hot topics.
We anticipate a strong agenda of knowledgeable experts in this field along with an exhibition of the latest commercial inspection technology and services.
We look forward to seeing you take part in the Forum!
John Shabushnig, PhD, Insight Pharma Consulting
Romain Veillon, GSK
SCIENTIFIC PROGRAMM PLANNING COMMITTEE:
John Shabushnig, Insight Pharma Consulting, Chair
Romain Veillon, GSK, Chair
John Ayres, Pharma Safety Solutions
Florian Krickl, Vitronic
Markus Lankers, MIBIC
Felix Riehn, Koerber Pharma
Hanns-Christian Mahler, ten23 Health
Andrea Sardella, Stevanato Group
Herve Soukassian, BD
Linda Wildling, Takeda
Jose Zanardi, Syntegon Technology
Janie Miller, PDA
Falk Klar, PDA
Stefanie Nebelin, Manager Programs & Events, PDA